These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8769703)

  • 1. Intensive combination chemotherapy in treatment of CML.
    Lengfelder E; Hehlmann R
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S55-7. PubMed ID: 8769703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose chemo-radiotherapy followed by autologous Philadelphia chromosome-negative blood progenitor cell transplantation in patients with chronic myelogenous leukemia.
    Carella AM; Chimirri F; Podestà M; Pitto A; Piaggio G; Dejana A; Lerma E; Pollicardo N; Vassallo F; Soracco M; Benvenuto F; Valbonesi M; Carlier P; Vimercati R; Prencipe E; Gatti AM; Ferrara RA; Incagliato M; Florio G; Frassoni F
    Bone Marrow Transplant; 1996 Feb; 17(2):201-5. PubMed ID: 8640167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
    Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-alpha-treated patients with chronic myelogenous leukemia show BCR/ABL-positive peripheral blood progenitor cells surviving long-term culture.
    Schultheis B; Heissig B; Pasternak G; Hörner S; Hehlmann R
    Folia Biol (Praha); 2000; 46(6):251-5. PubMed ID: 11140858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3.
    Aulitzky WE; Neubauer A; Kolbe K; Schneller F; Busemann C; Schleiermacher E; Peschel C; Siegert W; Huber C; Huhn D
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S67-9. PubMed ID: 8769707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alpha in the treatment of chronic myelogenous leukemia.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study of the combination of hydroxyurea and interferon alpha versus hydroxyurea monotherapy during the chronic phase of chronic myelogenous leukemia (CML Study II). The German CML Study Group.
    Hehlmann R; Heimpel H; Hossfeld DK; Hasford J; Kolb HJ; Löffler H; Pralle H; Queisser W; Hochhaus A; Tichelli A; Fett W; Schmitz N; Reiter A; Griesshammer M; Pfeifer W; Bümler M; Kamp T; Tobler A; Eimermacher H; Kuse R; Berger U; Ansari H
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S21-4. PubMed ID: 8769695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive treatment in order to minimize the Ph-positive clone in CML. Danish-Swedish CML Group.
    Simonsson B; Oberg G; Björeman M; Björkholm M; Carneskog J; Gahrton G; Hast R; Karl H; Lanng-Nielsen J; Löfvenberg E; Malm C; Turesson I; Udén AM; Vilén L; Weis-Bjerrum O
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S63-4. PubMed ID: 8769705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
    J Natl Cancer Inst; 1997 Nov; 89(21):1616-20. PubMed ID: 9362160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Value of interferon-alpha in treatment of chronic myeloid leukemia].
    Thaler J
    Acta Med Austriaca; 1993; 20(3):65-9. PubMed ID: 8368048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
    Schultheis B; Pasternak G; Hehlmann R
    Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic myelogenous leukemia].
    Ohnishi K
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1199-205. PubMed ID: 11579630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-alpha and cytosine arabinoside therapy in chronic myeloid leukemia.
    Ezaki K
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():279-84. PubMed ID: 10895166
    [No Abstract]   [Full Text] [Related]  

  • 19. [Bestatin therapy of chronic myelogenous leukemia].
    Uzuka Y; Saito Y
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):207-14. PubMed ID: 8434958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
    Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
    Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.